In situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics

  • T. N.C. Ramya
  • , Eranthie Weerapana
  • , Lujian Liao
  • , Ying Zeng
  • , Hiroaki Tateno
  • , Liang Liao
  • , John R. Yates
  • , Benjamin F. Cravatt
  • , James C. Paulson

Research output: Contribution to journalArticlepeer-review

69 Scopus citations

Abstract

CD22, a regulator of B-cell signaling, is a siglec that recognizes the sequence NeuAcα2-6Gal on glycoprotein glycans as ligands. CD22 interactions with glycoproteins on the same cell (in cis) and apposing cells (in trans) modulate its activity in B-cell receptor signaling. Although CD22 predominantly recognizes neighboring CD22 molecules as cis ligands on B-cells, little is known about the trans ligands on apposing cells. We conducted a proteomics scale study to identify candidate trans ligands of CD22 on B-cells by UV photocross-linking CD22-Fc chimera bound to B-cell glycoproteins engineered to carry sialic acids with a 9-aryl azide moiety. Using mass spectrometry-based quantitative proteomics to analyze the cross-linked products, 27 glycoproteins were identified as candidate trans ligands. Next, CD22 expressed on the surface of one cell was photocross-linked to glycoproteins on apposing B-cells followed by immunochemical analysis of the products with antibodies to the candidate ligands. Of the many candidate ligands, only the B-cell receptor IgM was found to be a major in situ trans ligand of CD22 that is selectively redistributed to the site of cell contact upon interaction with CD22 on the apposing cell.

Original languageEnglish
Pages (from-to)1339-1351
Number of pages13
JournalMolecular and Cellular Proteomics
Volume9
Issue number6
DOIs
StatePublished - Jun 2010
Externally publishedYes

Fingerprint

Dive into the research topics of 'In situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics'. Together they form a unique fingerprint.

Cite this